Pneumonia Due To Streptococcus — Patent Landscape
3
Approved drugs
21
Active US patents
58/100
Avg vulnerability
—
Annual revenue covered
Originators in Pneumonia Due To Streptococcus
Cliff calendar — next 15 years
3
26
1
27
1
28
1
29
5
30
1
33
6
34
2
36
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Amoxil
amoxicillin
|
Generic (originally Beecham/GSK) | 14 | 58 | — | 2026-12-08 |
|
Tygacil
TIGECYCLINE
|
Fresenius Kabi | 4 | 49 | — | 2028-10-24 |
|
Cleocin T
CLINDAMYCIN PHOSPHATE
|
Pfizer | 3 | 68 | — | 2026-12-02 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8299052 | Amoxil | method of use | 85 | 2027-05-07 |
| 9789057 | Cleocin T | method of use | 80 | 2026-12-02 |
| 8778924 | Amoxil | method of use | 80 | 2026-12-08 |
| 11931463 | Amoxil | method of use | 75 | 2034-02-12 |
| 11878011 | Amoxil | method of use | 75 | 2042-05-27 |
| 11129896 | Cleocin T | method of use | 70 | 2036-09-22 |
| 8357394 | Amoxil | formulation | 65 | 2026-12-08 |
| 9050263 | Amoxil | method of use | 62 | 2034-02-12 |
| 11135172 | Amoxil | method of use | 62 | 2034-02-12 |
| 9603806 | Amoxil | method of use | 62 | 2034-02-12 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 7977488 | Amoxil | composition of matter | 18 | 2030-04-10 |
| 7977488 | Amoxil | composition of matter | 18 | 2030-04-10 |
| 10238606 | Amoxil | formulation | 42 | 2034-02-12 |
| 9855335 | Tygacil | formulation | 42 | 2033-04-07 |
| 8372995 | Tygacil | formulation | 53 | 2030-10-08 |
| 12303563 | Cleocin T | formulation | 55 | 2036-09-22 |
| 8975242 | Tygacil | formulation | 55 | 2028-10-24 |
| 9186411 | Amoxil | formulation | 56 | 2030-08-11 |
| 9186411 | Amoxil | formulation | 56 | 2030-08-11 |
| 7879828 | Tygacil | formulation | 60 | 2029-02-05 |
Related
- Pneumonia Due To Streptococcus — full disease profile
- AI Patent Landscape Report — type "pneumonia due to streptococcus" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner